LBA02-07 PROSPECTIVE STUDY OF 68 GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING

Abstract

You have accessJournal of UrologyLate-breaking Abstract II - Malignant1 Sep 2021LBA02-07 PROSPECTIVE STUDY OF 68GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING Lucia Baratto, Hong Song, Heying Duan, Farshad Moradi, Guido Davidzon, and Andrei Iagaru Lucia BarattoLucia Baratto More articles by this author , Hong SongHong Song More articles by this author , Heying DuanHeying Duan More articles by this author , Farshad MoradiFarshad Moradi More articles by this author , Guido DavidzonGuido Davidzon More articles by this author , and Andrei IagaruAndrei Iagaru More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002149.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: 68Ga-RM2 is a synthetic bombesin receptor antagonist targeting gastrin-releasing peptide receptors (GRPr) that are overexpressed in several human tumors, including prostate cancer (PC). Men with biochemical recurrence (BCR) and negative CT/MRI and bone scintigraphy were evaluated for the presence of prostate cancer. METHODS: We enrolled 127 men with BCR PC, 45-83-year-old (mean±SD: 68.3±6.9). Imaging started at 40-89 minutes (mean±SD: 51.0±8.9) after injection of 113.8-152.6 MBq (mean±SD: 140.5±6.4) of 68Ga-RM2 using a time-of-flight (TOF)-enabled simultaneous positron emission tomography (PET) / magnetic resonance imaging (MRI) scanner. RESULTS: All patients had rising PSA and negative conventional imaging prior to enrollment. 68Ga-RM2 PET identified recurrent PC in 85 of the 127 participants. Positivity rate of 68Ga-RM2 PET was: 37.9% for PSA <0.5 ng/dl (n=29), 61.1% for PSA 0.5 – 1.0 ng/dl (n=18), 64.7% for PSA 1.0 – 2.0 ng/dl (n=17), 82.6% for PSA 2.0 – 5.0 ng/dl (n=23) and 87.5% for PSA >5.0 ng/dl (n=40). PSA velocity values were 1.9±2.7 ng/ml/year (range: 0-9.1) in patients with negative PET scans and 5.8±9 ng/ml/year (range: 0.2-45.4) in patients with positive PET scans (P: 0.01). CONCLUSIONS: 68Ga-RM2 PET identifies GRPr expression in BCR PC lesions despite negative conventional imaging, indicating it is a promising PET radiopharmaceutical in this clinical scenario. 68Ga-RM2 may identify higher risk patients given the highly statistically significant difference PSA velocity values between patients with negative and positive scans and may be a complementary radiopharmaceutical to the PSMA-targeting tracers to ultimately allow for personalized medicine. Source of Funding: DoD © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1178-e1178 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lucia Baratto More articles by this author Hong Song More articles by this author Heying Duan More articles by this author Farshad Moradi More articles by this author Guido Davidzon More articles by this author Andrei Iagaru More articles by this author Expand All Advertisement Loading ...